DONNINGTON LABORATORIES LIMITED

1. Credit Opinion: APPROVE Donnington Laboratories Limited presents a robust balance sheet with substantial net assets and an exceptionally strong current ratio, indicating ample capacity to service debt obligations. The company operates with virtually no third-party debt and maintains a healthy cash position. However, the approval carries a condition: a significant portion of the company's assets (over 50% of total assets) consists of amounts owed by group undertakings. Therefore, this credit opinion is contingent upon the broader group's financial stability and the collectability of these intercompany balances. Assuming the group entity is solvent, the company represents a low credit risk.

2. Financial Strength The company exhibits exceptional financial strength from a balance sheet perspective. Net assets stand at £1.15 million (up from £1.12 million in 2024), representing a steady accumulation of wealth over its 25-year history. Total liabilities are remarkably low at just £82.6k, resulting in a very low leverage position.

However, the quality of the assets requires scrutiny. Of the £743.5k in debtors, £640.3k is owed by group undertakings. This intercompany loan represents the single largest asset on the balance sheet and over 55% of total assets. While the £500 share capital and £1.146m profit and loss reserve demonstrate long-term retention of earnings, the company's true standalone financial resilience is heavily dependent on the ability of its group partners to honor this internal debt. Excluding this intercompany exposure, the company's independent operating assets are relatively modest.

3. Cash Flow Assessment Liquidity is extremely strong in absolute terms. The company holds £423.8k in cash, which alone is more than five times its total current liabilities (£82.6k). The current ratio is approximately 14.3:1, meaning the business has more than sufficient current assets to cover its short-term obligations.

Working capital management appears stable, with third-party trade debtors decreasing slightly from £140.1k to £103.1k, and trade creditors increasing modestly from £13.8k to £15.5k. Cash flow from third-party operations appears to be steady but modest; the P&L reserve only increased by roughly £31k during the year, suggesting a relatively low profit margin relative to the balance sheet size. The primary cash flow risk is that the £640k intercompany receivable may not be readily convertible to cash if the wider group faces liquidity constraints.

4. Monitoring Points * Intercompany Dependence: The £640.3k owed by group undertakings is the critical vulnerability. Any credit facility should monitor the financial health of the wider group, and covenants should be considered to prevent the stripping of this asset or the assumption of further intercompany loans to the detriment of creditors. * Profitability Margins: Net assets grew by only £31k despite a £1.15m equity base. Monitor future P&L reserves to ensure the business is generating sufficient trading profit from its core technical testing operations rather than relying on group financing structures. * Staffing Levels: Employee headcount dropped from 13 to 12. Given the specialized nature of the technical testing and analysis sector (SIC 71200), key-person risk and the impact of staff reductions on service capacity should be noted. * Group Structure: PSCs include Mr John Reed (who controls >75% of shares/voting) and Ms Lesley Spice (25-50%), while the sole director is Martin Isom. Ensure that corporate governance and director authority align with the bank's requirements, particularly given the control exerted by non-director PSCs.